Injective vs Scallop — how do they compare? Injective trades at Rp92,485 (market cap Rp9,26T, Rp1,73T 24h volume), while Scallop trades at Rp167.58 (market cap Rp25,24M, Rp12,14M 24h volume). The key difference: Injective is far larger — about 366878× Scallop's market cap, and Scallop's supply is capped (163,5M / 250M SCA (66%)) while Injective's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Injective for 36 Days and Scallop for 13 Days on average.
| INJ | SCA | |
|---|---|---|
Market Cap | Rp9,26T | Rp25,24M |
Volume (24h) | Rp1,73T | Rp12,14M |
Circulating Supply | 100M INJ | 163,5M / 250M SCA (66%) |
Typical Hold Time | 36 Days | 13 Days |
Signals from Pluang's Aura AI — not financial advice
Injective (INJ) is trading at Rp92,221 with a market cap of Rp9.18T, showing a bullish technical signal overall. The moving averages are strongly bullish, while oscillators are neutral. Key resistance lies at Rp93,589 and support at Rp86,188. The asset has a hold time of 36 days, indicating moderate holding behavior. No major protocol updates or ecosystem news are noted recently, but the token remains active in decentralized exchange and DeFi sectors.
Overall outlook is cautiously optimistic due to bullish technicals, but risks include high volatility and neutral oscillators suggesting potential consolidation. Opportunities lie in continued ecosystem growth, while major risks involve crypto market sentiment shifts and regulatory uncertainties. Investors should monitor key resistance levels for breakout signals.
Scallop (SCA) is trading at Rp168.32 with a market cap of Rp25.17 million, showing bullish technical signals despite bearish moving averages. The token has 66% of its max supply in circulation with an average hold time of 13 days. Recent ETF inclusion by GraniteShares in May 2026 provides institutional exposure, though the news articles reference equity ETFs rather than direct cryptocurrency developments.
Overall outlook is cautiously optimistic with technical strength but limited fundamental catalysts. Key opportunities include institutional ETF exposure and neutral oscillator positioning. Major risks include high RSI_6 at 89.40 (overbought), low market cap vulnerability, and the token's relatively new market presence requiring careful risk management.
What Pluang investors did over the last 30 days
Latest headlines on both assets
Injective enables access to unlimited DeFi markets. Users can create any financial market on Injective's fast, cross-chain, zero gas fee, secure, and fully decentralized exchange protocol. The trading infrastructure of Injective is supported entirely by a central limit order book that integrates the user-friendly interface and speed of centralized exchanges with the transparency of decentralized exchanges. Native token INJ is a scarce asset that used for governance, exchange value capture, liquidity mining, and staking.
Read more on INJ →Scallop is an advanced decentralized finance (DeFi) protocol built on the Sui blockchain. It offers a wide range of financial services, including lending, borrowing, automated market making (AMM), and asset management. Developed by Scallop Labs, which has a team of experts in DeFi, cybersecurity, and fintech, Scallop has attracted support from notable investors such as CMS Holdings, 6th Man Ventures, KuCoin Labs, and Mysten Labs. Additionally, it is the first DeFi project to receive an official grant from the Sui Foundation, highlighting its institutional-grade quality and strong security features.
Read more on SCA →